Cancer cells swap mitochondria to disarm T cells, and PD-L1's cis partnership with CD80 drives dendritic migration.
Cancer cells make tunneling nanotubules that reach the neurons innervating them, pop the straw into the neuron and suck off its mitochondria. The 2025 Nature paper, Nerve to Cancer Transfer of Mitochondria During Cancer Metastasis, showed this in glioblastoma, where nerves sit right against the tumor cells.
Answered around 6:25Cancer growth and metastasis is a high energy thing: the cells grow like mad and have a very high metabolic rate, so they demand high levels of mitochondria. They can duplicate their own, but they also simply steal them from nearby cells such as neurons.
Answered around 5:18It donates back its own defective, mutated mitochondria. The T cell takes them up, loses its ability to generate its own energy, and becomes exhausted and senescent. It is a dual benefit: the cancer gets good mitochondria and hands its foe the bad ones.
Answered around 12:18Mechanistically, the cancer mitochondria carry an associated protein called USP30 that protects them from degradation, so the cancer cell limits mitophagy and keeps its mitochondrial biomass high. Once transferred, those mitochondria stay resistant to mitophagy inside the T cell, which therefore cannot turn them over.
Answered around 17:29The T cell keeps turning over its own mitochondria on its normal schedule, but the transferred defective ones cannot be turned over. Its own all go away, leaving only defective mitochondria, a state they called homoplasmy, and the T cell becomes exhausted, senescent and poorly functional.
Answered around 18:17They show some drugs can block extracellular vesicle release or block nanotube formation, and combined with checkpoint therapy they get better therapy. The idea is to prevent transfer of the worse mitochondria to the T cells, so the T cells keep their energy capacity and stay anti-tumor.
Answered around 20:16They are also transferred by extracellular vesicles, gap junction channels and cell fusion; a cell can bud off its mitochondria and give them to someone else in the area. Horizontal mitochondrial transfer, HMT, happens normally and under pathological conditions, and has been known for twenty years.
Answered around 24:19Blocking PD-L1 also blocks the cis interaction that dendritic cells need to migrate to the draining lymph node, so you inhibit the migration that brings antigen to T cells. Anti-PD-1 does not change migration. Nobody knew about this migration role until this paper.
Answered around 45:08The antibody that blocks migration binds a site on PD-L1 previously associated with PD-L1 interacting with CD80, the B7-1 molecule, on the same dendritic cell. That cis interaction, not the usual trans interaction with PD-1 on another cell, is what the migration phenotype depends on.
Answered around 38:15In a mouse psoriasis model driven by the toll-like receptor drug imiquimod, blocking PD-L1 with either the antibody or the mutation ameliorated the psoriasis; the mice showed no dendritic cell migration to the lymph node and fewer Th17 cells. Blocking migration helps in autoimmune and autoinflammatory settings.
Answered around 57:18“But disinformation is when you purposely mislead people, like saying the polio vaccine kills more people than it helps, which is complete disinformation.”
“So they want to steal the mitochondria from their neighboring cells.”
“So if they don't have CD80 and PD-L1 on the same cell, the cells can't migrate.”
“But we could imagine situations where we would want to block dendritic cell migration.”
“Mitochondrial Transfer in Cancer Metastasis.” https://traffic.libsyn.com/secure/immune/Immune095.mp3. Transcript summary by WhipScribe, https://whipscribe.com/transcript-pages/mitochondrial-transfer-in-cancer-metastasis.html.